Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cypress Bioscience, a provider of personalized medicine laboratory services, has completed a transaction to acquire Cellatope's technology platform that uses cell-bound complement activation products to diagnose and monitor debilitating autoimmune disorders, including systemic lupus erythematosus.
Subscribe to our email newsletter
Cypress said that the acquisition is consistent with its strategy of providing innovative products and services that address unmet medical needs in the fields of rheumatology and pain.
The cell-bound complement activation products (CB-CAP) technology was developed by Joseph Ahearn and Susan Manzi at the Lupus Center for Excellence at the University of Pittsburgh, to evaluate cell-bound fragments of activated complement proteins and their utility in improved diagnosis and monitoring of systemic lupus erythematosus (lupus) patients.
In connection with this asset purchase, Cypress will be assuming a license from the University of Pittsburgh. Cypress plans to complete the development program and add these important lupus personalized medicine services to the current Avise product line, which includes tests for diagnosis, prognosis and monitoring treatment of rheumatoid arthritis.
Cypress acquired the CB-CAP technology in a transaction that included a $2 million cash payment for the diagnostic technology to Cellatope as well as an additional $3 million potential milestone payment associated with the commercial development of the CB-CAP monitoring technology for lupus.